1 of 1
Story summary
- AstraZeneca Chief Executive Pascal Soriot called the UK drug pricing deal a very positive step.
- He said it is unlikely to restart the paused £200 million Cambridge investment.
- Soriot warned the UK-US NHS deal may not support innovative products.
- Enhertu was not recommended for NHS use.
- AstraZeneca aims for $80 billion in annual sales by 2030 after last year's 8% rise to $58.7 billion, aided by cancer drugs.
